

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6053080

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
KATHLEEN E CLARENCE-SMTIH	07/09/2018
GT BIOPHARMA, INC.	09/19/2019
RECEIVING PARTY DATA	
Name:	DAS-MG, INC
Street Address:	756 EAST 4TH STREET, #1
City:	BOSTON
State/Country:	MASSACHUSETTS
Postal Code:	02127
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16752591
CORRESPONDENCE DATA	
Fax Number:	(888)229-5239
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	7605937503
Email:	docketing@transformativelegal.com
Correspondent Name:	TRANSFORMATIVE LEGAL, LLC
Address Line 1:	P.O. BOX 15007
Address Line 4:	SCOTTSDALE, ARIZONA 85267
ATTORNEY DOCKET NUMBER:	DAS1731USCDX
NAME OF SUBMITTER:	BECKY ANWEILER
SIGNATURE:	/Becky Anweiler/
DATE SIGNED:	04/08/2020
Total Attachments: 5	
source=PRV62695497#page1.tif	
source=DAS Executed Assignment#page1.tif	
source=DAS Executed Assignment#page2.tif	
source=DAS Executed Assignment#page3.tif	
source=DAS Executed Assignment#page4.tif	

Assignment

Whereas, I, Kathleen E. CLARENCE-SMITH of 1825 K. Street, N.W., Suite 510, Washington, DC 20006-1236, hereinafter called assignor, have invented certain improvements in NEOSTIGMINE PHARMACEUTICAL COMBINATION FOR TREATING MYASTHENIA GRAVIS and filed a United States Provisional Patent Application therefor; and


Whereas, GT BIOPHARMA, INC. of 1825 K. Street, N.W., Suite 510, Washington, DC 20006-1236, (assignee), desires to acquire the entire right, title, and interest in the Provisional application and invention, and to any United States patents to be obtained therefor;

Now therefore, for valuable consideration, receipt whereof is hereby acknowledged,

I, the above named assignor, hereby sell, assign and transfer to the above named assignee, its successors and assigns, the entire right, title and interest in the Provisional application and the invention disclosed therein for the United States of America, including any United States application claiming priority or converted from the Provisional application and all divisions, and continuations thereof, and all Letters Patent of the United States that may be granted thereon, and all reissues thereof, and all countries foreign thereto, including rights of priority under the International Convention of Paris (1883) as amended, including the right to claim priority under 35 U.S.C. §119 and the right to sue for past damages, and I request the Director of the U.S. Patent and Trademark Office to issue any Letters Patent granted upon the invention set forth in any United States application claiming priority or converted from the Provisional application to the assignee, its successors and assigns; and I hereby agree that the assignee may apply for foreign Letters Patent on the invention and I will execute without further consideration all papers deemed necessary by the assignee in connection with any United States and foreign applications claiming priority or converted from the Provisional application when called upon to do so by the assignee.

I hereby authorize and request my attorneys SUGHRUE MION, PLLC of 2100 Pennsylvania Avenue, NW, Washington, DC 20037-3213 to insert here in parentheses (Application number 62/695,497 and Confirmation number 1919, filed July 9, 2018) the application number, confirmation number and filing date of said application when known.

Date: 07/09/2018



s/Kathleen CLARENCE-SMITH

(Legalization not required for recording but is prima facie evidence of execution under 35 U.S.C. §261)

Exhibit C
PATENT ASSIGNMENT

WHEREAS, GT BIOPHARMA, INC., a Delaware corporation, with an address of 9350 Wilshire Blvd., Suite 203, Beverly Hills, CA 90212 (hereinafter "ASSIGNOR"), is the owner of owner of the entire right, title and interest, described in the patent applications listed in the attached Appendix (hereinafter the "Assigned Applications");

WHEREAS, DAS-MG, INC., a Delaware corporation located at 756 East 4th Street, #1, Boston, MA 02127 (hereinafter "ASSIGNEE"), is desirous of acquiring from ASSIGNOR, ASSIGNOR'S entire right, title, and interest in and to said invention(s) described in the Assigned Applications and in any Letters Patent that may be granted therefor in the United States of America and in any foreign countries, to and under the Assigned Applications and the invention(s) described therein.

NOW, THEREFORE, for good and valuable consideration provided by ASSIGNEE to ASSIGNOR pursuant to the provisions of that certain Asset Purchase Agreement entered into this same day between ASSIGNEE and ASSIGNOR, including ASSIGNOR's promise to pay and payment of the Initial Purchase Price under Section 3.1 of the Asset Purchase Agreement, the receipt and sufficiency of which as consideration for this Assignment being hereby acknowledged by ASSIGNOR, ASSIGNOR hereby sells, assigns and transfers to ASSIGNEE, its successors, legal representatives, or assigns, contingent on ASSIGNOR's receipt of the Initial Purchase Price, ASSIGNOR'S full and exclusive rights, titles and interests to said invention(s) described in the Assigned Applications and in any patent(s) that may arise therefrom in the United States of America, its territories, dependencies and possessions, and in any and all countries foreign thereto, including rights of priority under the International Convention of Paris (1883) as amended, including the right to claim priority under 35 U.S.C. §119; and in any and all patent applications similarly describing the invention(s) or that claim priority to the above-referenced patent application and any and all patents arising therefrom, and any and all patent applications to which the application claims priority, including, without limitation, any and all continuations, continuations-in-part, divisions, renewals, extensions, substitutions, replacements, or reissues of any such patent applications, and every priority right that is or may be predicated upon or arise from any such applications or patents, for the full term or terms for which the same may be granted.

ASSIGNOR hereby covenants that ASSIGNOR has full right to convey the entire right, title, and interest herein assigned and transferred. ASSIGNOR will, at any time, when called upon to do so by the ASSIGNEE, its successors, legal representatives, or assigns, and without further compensation, execute and deliver any and all lawful papers (including, but not limited to, granting powers of attorney and executing inventor declarations for ASSIGNOR's interest in the invention(s) embodied in continuations-in-part of the above-referenced patent application or of any related patent application or patent); make all rightful oaths, affidavits, or declarations; and perform all other lawful acts that may be deemed by ASSIGNEE reasonably necessary or desirable to obtain, secure, and/or vest the benefit of the rights herein assigned, and perfect the title to said discoveries and/or inventions, said patent applications, and all patents and all related

rights thereto in the name of and for the benefit for the ASSIGNEE, its successors, legal representatives, or assigns, and to assist or enable the ASSIGNEE, its successors, legal representatives, or assigns to enforce, protect, or otherwise benefit from the rights in said discoveries and/or inventions, applications, and patents hereby granted.

The ASSIGNOR hereby authorizes and requests the Director of the U.S. Patent and Trademark Office, and Patent and Trademark Officials in any foreign countries to issue any and all Letters Patent resulting from said Assigned Applications or any and all continuations, continuations-in-part, divisions, renewals, extensions, substitutions, replacements, or reissues of any such patent applications thereof to said ASSIGNEE, as ASSIGNEE of the entire interest.

This ASSIGNMENT shall be binding upon ASSIGNOR'S successors, and/or its assigns, and is effective automatically upon completion of all of the closing conditions set forth in Section 4.2 of that certain Asset Purchase Agreement between ASSIGNEE and ASSIGNOR, including the payment of the Initial Purchase Price Payment in accordance with Section 3.1 of the Asset Purchase Agreement. For the avoidance of doubt, this Assignment will have no effect unless and until ASSIGNEE receives the Initial Purchase Price payment.

I am empowered to assign this Assignment on behalf of GT BIOPHARMA, INC.

GT BIOPHARMA, INC.

Date: _____

s/ 

Name: Anthony Cataldi

Title: Chairman & Chief Executive Officer

Accepted By:

DAS-MG, INC.

Date: _____

s/ _____

Name: _____

Title: _____

(Legalization not required for recording but is prima facie evidence of execution under 35 U.S.C. §261)

rights thereto in the name of and for the benefit for the ASSIGNEE, its successors, legal representatives, or assigns, and to assist or enable the ASSIGNEE, its successors, legal representatives, or assigns to enforce, protect, or otherwise benefit from the rights in said discoveries and/or inventions, applications, and patents hereby granted.

The ASSIGNOR hereby authorizes and requests the Director of the U.S. Patent and Trademark Office, and Patent and Trademark Officials in any foreign countries to issue any and all Letters Patent resulting from said Assigned Applications or any and all continuations, continuations-in-part, divisions, renewals, extensions, substitutions, replacements, or reissues of any such patent applications thereof to said ASSIGNEE, as ASSIGNEE of the entire interest.

This ASSIGNMENT shall be binding upon ASSIGNOR'S successors, and/or its assigns, and is effective automatically upon completion of all of the closing conditions set forth in Section 4.2 of that certain Asset Purchase Agreement between ASSIGNEE and ASSIGNOR, including the payment of the Initial Purchase Price Payment in accordance with Section 3.1 of the Asset Purchase Agreement. For the avoidance of doubt, this Assignment will have no effect unless and until ASSIGNEE receives the Initial Purchase Price payment.

I am empowered to assign this Assignment on behalf of GT BIOPHARMA, INC.

GT BIOPHARMA, INC.

Date: _____

s/ _____

Name: Anthony Cataldo

Title: Chairman & Chief Executive Officer

Accepted By:

DAS-MG, INC.

Date: 4/14/19

s/ [Signature]

Name: Thomas A. Datta

Title: CEO

(Legalization not required for recording but is prima facie evidence of execution under 35 U.S.C. §261)

APPENDIX

Application No.	Filing Date	Recordation of Assignment
US 62/443,904	January 9, 2017	November 3, 2017 at REEL 044025, FRAME 0080
PCT/US18/12754	January 8, 2018	
ROC (Taiwan) 107100813	January 9, 2018	
US 16/476,460	July 8, 2019	
US 62/536,595	July 25, 2017	November 3, 2017 at REEL 044025, FRAME 0113
US 62/695,462	July 9, 2018	July 10, 2018 at REEL 046301, FRAME 0771
PCT/US18/43636	July 25, 2018	
ROC (Taiwan) 107125761	July 25, 2018	
US 62/449,699	January 24, 2017	November 3, 2017 at REEL 044025, FRAME 0166
PCT/US18/14901	January 23, 2018	
US 16/480,177	July 23, 2019	
ROC (Taiwan) 107102591	January 24, 2018	
US 62/536,580	July 25, 2017	November 3, 2017 at REEL 044025, FRAME 0185
US 62/695,497	July 9, 2018	July 10, 2018 at REEL 046301, FRAME 0840
PCT/US/19/40548	July 3, 2019	
PCT/US18/43391	July 25, 2018	
ROC (Taiwan) 107125758	July 25, 2018	